%0 Consensus Development Conference
%T Oligo safety working group exaggerated pharmacology subcommittee consensus document.
%A Kornbrust D
%A Cavagnaro J
%A Levin A
%A Foy J
%A Pavco P
%A Gamba-Vitalo C
%A Guimond A
%J Nucleic Acid Ther
%V 23
%N 1
%D Feb 2013
%M 23289535
%F 4.244
%R 10.1089/nat.2012.0399
%X This document summarizes the current consensus opinion of the Exaggerated Pharmacology (EP) Subcommittee of the Oligonucleotide Safety Working Group on the appropriate strategies to assess potential adverse effects caused by an "exaggerated" degree of the intended pharmacologic activity of an oligonucleotide (ON). The Subcommittee focused its discussions primarily on the ON subclasses that impact expression of "host" (i.e., human gene products--antisense, small interfering RNAs, and related ONs that target messenger RNA), with later and more limited discussions on aptamer, immunostimulatory, and microRNA subclasses. It is expected that many of these principles will be relevant to other subclasses but will need to be carefully considered as those development programs advance towards clinical trials. The recommendations may also serve as a frame of reference when designing Good Laboratory Practice safety studies with ONs, with regard to the study design elements that address assessment of EP. It is also hoped that these recommendations will establish a foundation for discussion with regulatory agencies on this subject.